VISION: tepotinib in MET exon 14 skipping NSCLC

Xiuning Le, MD PhD, The University of Texas MD Anderson Cancer Centre, Houston, TX, reports the notable outcomes of the Phase II VISION trial (NCT02864992) of tepotinib, a MET tyrosine kinase inhibitor (TKI), in MET exon 14 (METex14) skipping non-small cell lung cancer (NSCLC). The study investigated baseline characteristics that could indicate positive or negative clinical outcomes. Increased activity in the MET pathway was correlated with a stronger tumour response, whereas increased action in KRAS or BRAF pathways was observed in patients with a poorer response. Circulating tumor DNA (ctDNA) clearance also demonstrated correlations to treatment response; patients with undetectable ctDNA from entry or with a significant decrease in the trial exhibited a strong response to tepotinib, but patients with an increase in ctDNA during the study experienced a poor response. In addition, ctDNA dynamics were useful in understanding tumour resistance. Dr Le emphasised the importance of this data for future approaches in therapy selection, intensification and prediction for NSCLC. This interview took place at the 2023 World Conference on Lung Cancer (WCLC) in Singapore, Singapore.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.